about
Expression of alpha-thymosins in human tissues in normal and abnormal growthImpact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifenEstrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.BRCA2 gene mutations in Greek patients with familial breast cancerThe MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.Carcinosarcoma of the submandibular salivary gland.Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypesManaging bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.Adiponectin and breast cancer risk.Breast cancer in ectopic breast tissue.Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialDose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialShould women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?Older patients with breast cancer: is there bias in the treatment they receive?A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.Paraffinomas of the breast or oleogranulomatous mastitis-a rare entity.Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.Wire localisation biopsy of non-palpable breast lesions: reasons for unsuccessful excision.Glycogen-rich clear cell carcinoma of the breastThe Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies.White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma.Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialA new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferonImpact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.Controversial issues in the management of older adults with early breast cancer.The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?Does patient education work in breast cancer? Final results from the global CARIATIDE study.Breast cancer in the elderly: reducing the losses.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Solitary spleen metastasis and amyloidosis in a patient with endometrial cancer.
P50
Q24564638-ECF71328-D232-49E0-AC27-87514D835648Q27026180-9E1CBD8E-ED7D-41B8-8942-4CBC40A769C8Q27851630-FDB02C51-FB51-4A90-95A4-27EF1B6BC3D6Q28213349-B9AA91CA-3285-4C46-8C73-29FAF3A4DF1AQ30313224-01B56D10-4DF6-415D-9647-4A9CB6AC7294Q33366949-5DF2F9AE-6251-4534-A7C4-1D548FBC658AQ33372691-6B5FC22E-98BF-4119-9F53-C1A4F0382901Q33377581-3B708206-5676-483D-AEA6-18DE8CD8BAA8Q33385368-5B44FEC4-CE9E-4A68-938C-5012E1C0545BQ33670672-36DF4804-C9D8-4561-8687-EE697CEE301BQ33889548-652B3C7E-17D2-4788-A54B-5325A8FE24B0Q34171441-FEB184D1-F8B7-4DC4-A1CE-C45F635C89B8Q34173455-137435BB-8610-473C-8445-CE6E7E8BB584Q34269292-EDD320A2-1F1C-45D7-A360-199FFFFC2466Q34303243-5C363242-5491-4C60-878A-311BD77F4049Q34304163-0F5EAEE3-BBDA-44AD-BFB0-5D9E2716976CQ34335379-5DB96B42-C9FB-43C4-84A0-386CDB174BB6Q34468964-42FAA31F-E07B-4F38-90AC-113C75517699Q36175750-BD6B194C-E464-4662-A34C-305B53D53C5AQ36348460-296A33E2-75DF-4E70-9D6C-1B81F3D90470Q36373710-9610DAC1-D600-4D3F-ADEC-4381C1140BF6Q36424438-AC49DD22-FDE3-4F24-9967-F46CC1E4C890Q36438383-F5F8377B-52AE-4381-91E6-7FAF5A24700EQ36519234-25F413AF-8509-4B24-8E54-36DC5864B112Q36660722-D5879C7C-1914-49C7-9036-0805212EE304Q36922539-6314A72E-13F8-44BF-92C3-51852C20DF0CQ37107759-A0CF578E-14FF-4BCD-88A3-FDE5D9AEBB33Q37279308-22305399-0F9D-4E52-B53C-56B4891E6023Q37520710-B77C7E05-8118-4D7D-AEB1-28DCD25903F3Q38392241-CAB073E9-2C1F-4D23-B51D-889F1768A829Q38667656-FF2F27A0-CA98-49AF-BADA-EE489AF1119EQ38673148-58C5CC8E-B644-4E56-8AA6-4085CE0B7B12Q38699879-4793A211-5EC8-4C6E-9292-B7D2B4683E8FQ38731511-EBEB327F-E85C-4688-8068-A9A20CAC65BFQ38759878-3F8839EB-961A-460A-AE66-BC93FFE0F74BQ38957598-713AA561-C991-44C6-971C-4A662AD2CA38Q39057658-A1AA2AEA-A8DC-4F39-AABE-1BFA544EE07FQ39360801-A44F1E05-BF85-46E2-BC75-147811D236F4Q39638185-AA348ECD-881C-4248-9746-2DEF80D80BC6Q40532961-E63AF2DF-0EA5-46E7-A04A-A208E7A970EA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christos Markopoulos
@ast
Christos Markopoulos
@en
Christos Markopoulos
@es
Christos Markopoulos
@nl
type
label
Christos Markopoulos
@ast
Christos Markopoulos
@en
Christos Markopoulos
@es
Christos Markopoulos
@nl
prefLabel
Christos Markopoulos
@ast
Christos Markopoulos
@en
Christos Markopoulos
@es
Christos Markopoulos
@nl
P106
P1153
7007164817
P31
P496
0000-0002-5072-6390